Brickell Biotech Stock

Brickell Biotech Equity

Delisted

The The Equity of Brickell Biotech (BBI) as of Aug 20, 2026 is 7.19 M USD. In the previous year, The Equity was 24.91 M USD — a change of -71.12% (lower).

Equity

7.19 MUSD

YoY

-71.12%

Last updated:

In 2026, Brickell Biotech's equity was 7.19 M USD, a -71.12% increase from the 24.91 M USD equity in the previous year.

Access this data via the Eulerpool API

Brickell Biotech Stock analysis

What does Brickell Biotech do? Brickell Biotech Inc is a biopharmaceutical company that focuses on the development and marketing of innovative dermatology products. The company was founded in 2009 and is headquartered in Boulder, Colorado (USA), with branches in California and Singapore. The history of Brickell Biotech dates back to the 1960s when the company was originally founded under the name Brickell Research Inc. Over the following decades, the company specialized in biological research and conducted important research that forms the basis for today's product development. Brickell Biotech's business model is based on the creation of new and innovative therapies for the treatment of various dermatological diseases. In recent years, the company has entered into a number of important partnerships to accelerate its product development and strengthen its position in the industry. Brickell Biotech operates in two main areas: pharmaceuticals and cosmetic products. In the pharmaceuticals area, the company has a number of promising therapies in the pipeline that target the treatment of skin cancer, psoriasis, and other dermatological conditions. The company's flagship product is Sofpironium Bromide, a potential treatment for hyperhidrosis (excessive sweating). In the cosmetic products area, the company has developed a range of skincare products tailored to the needs of people with sensitive, dry, or aging skin. These products include moisturizers, cleansers, and anti-aging products, all made from high-quality ingredients. Brickell Biotech works closely with the scientific community to explore the latest developments and innovations in dermatology and the cosmetics industry. The company has also established a strong presence in the medical and research sectors by collaborating closely with leading universities and medical institutions worldwide. Overall, Brickell Biotech is a promising company in the biopharmaceutical and cosmetics industry, specializing in the development of new and innovative therapies for the treatment of skin conditions. With a strong pipeline of products and a dedicated leadership team, the company is expected to continue growing and establish itself as an important player in the industry. Brickell Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Brickell Biotech's Equity

Brickell Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Brickell Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Brickell Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Brickell Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Brickell Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Brickell Biotech stock

The Equity of Brickell Biotech is 7.19 M USD in 2026.

The Equity of Brickell Biotech changed from 24.91 M USD to 7.19 M USD, representing a -71.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Brickell Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Brickell Biotech historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Brickell Biotech

All Key Metrics — Brickell Biotech